Relationship between 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene and obesity in Argentinian Hispanic adults

Blood Coagulation and Fibrinolysis

Volumn 21, Issue 2, 2010, Pages 196-198

  Wingeyer, Silvia D Perés ^a   Belli, Susana H ^b   Graffigna, Mabel N ^b   Levalle, Oscar ^b   De Larrañaga, Gabriela F ^a  

^a HOSPITAL F J MUÑIZ   (Argentina)

^b HOSPITAL DURAND   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; ARGENTINA; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; HISPANIC; HUMAN; INSULIN SENSITIVITY; LETTER; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; WAIST CIRCUMFERENCE;

ADULT; ARGENTINA; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HISPANIC AMERICANS; HUMANS; MALE; OBESITY; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC;

EID: 76449094261     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e328334652b     Document Type: Letter

References (15)

1. Duygu O, Huseyin A, Nejat A. The effect of plasminogen activator inhibitor-1-675 4G/5G polymorphism on PAI-1 gene expression and adipocyte differentiation. Clin Apl Thromb Hemost 2008; 14:438-446.
2. Jeffery R, Sherwood N. Is the obesity epidemic exaggerated? No. BMJ 2008; 336:245.
3. Alessi M, Juhan-Vague I. PAI- and the metabolic syndrome: links, causes and consequences. Arterioscler Thromb Vasc Biol 2006; 26:2200-2207.
4. Solá E, Vayá A, España F, Castelló R, Ramó n L, Hernandez-Mijares A, et al. Plasminogen activator inhibitor-1levels in severe and morbid obesity. Effect of weight loss and influence of weight loss and influence of 4G/5G polymorphism. Thromb Res 2008; 122:320-327.
5. Ma L-J, Mao S-L, Taylor KL, Talerngsak K, YouFei G, YaHua Zv, et al. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 2004; 53:336-346.
6. Lijnen H, Alessi M, Van Hoef B, Collen D, Vague J. On the role of plasminogen activator inhibitor-1 in adipose tissue development and insulin resistance in mice. J Thromb Haemost 2005; 3:1174-1179.
7. Bastarrachea RA, Shelley AC, Comuzzie AG. Genomics of body weight regulation: unraveling the molecular mechanisms predisposing to obesity. Med Clin (Barc) 2004; 123:104-117.
8. Naran N, Chetty N, Crowther N. The influence of metabolic syndrome components on plasma PAI-1 concentrations is modified by the PAI-1 4G/5G genotype and ethnicity. Atherosclerosis 2008; 196:155-163.
9. Bensen J, Hsu F, Brown W, Sutton B, Norris J, Tracy R, et al. Association analysis of the plasminogen activator inhibitor-1 4G/5G polymorphism in Hispanics and African Americans: the IRAS Family study. Hum Hered 2004; 57:128-137.
10. Kinik S, Ozbek N, Yuce M, Yazici A, Verdi H, Atac F. PAI-1 gene 4G/5G polymorphism, cytokine levels and their relations with metabolic parameters in obese children. Thromb Haemost 2008; 99:352-356.
11. Hoffstedt J, Andersson L, Persson L, Isaksson B, Arner P. The common -675 4G/5G polymorphism in the plasminogen activator inhibitor-1gene is strongly associated with obesity. Diabetología 2002; 45:584-587.
12. Freeman M, Mansfield M, Barrett J, Grant P. Genetic contribution to circulating levels of hemostatic factors in healthy families with effects of knows genetic polymorphisms on heritability. Artherioscler Thromb Vasc Biol 2002; 22:506-510.
13. Estellé s A, Dalmau J, Falcó C, Berbel O, Castelló R, España F, et al. Plasma PAI-1 levels in obese children: effect of weight loss and influence of PAI1 promoter 4G/5G genotype. Thromb Haemost 2001; 86:647-652.
14. Sartori M, Vettor R, De Pergola G, De Mitrio V, Saggiorato G, Della Mea P, et al. Role of the 4G/5G polymorphism of PAI-1 promoter on PAI-1 levels in obese patients. Thromb Haemost 2001; 86:1161-1169.
15. de Larrañaga G, Peré s Wingeyer S, Graffigna M, Belli S, Bendezú K, Alvarez S, et al. Plasma plasminogen activator inhibitor-1 levels and nonalcoholic fatty liver in individuals with features of metabolic syndrome. Clin Apl Thromb Hemost 2008; 14:319-324.